CJC-1295 (No DAC) and 5-Amino-1MQ: What Combination Research Shows

Overview of CJC-1295 (No DAC) and 5-Amino-1MQ in Preclinical Science

In modern biochemical research, evaluating compounds with complementary mechanisms of action provides critical insight into synergistic cellular responses. When studying tissue regeneration, cellular energy expenditure, and metabolic rate, single-pathway interventions often present analytical limitations. Consequently, researchers frequently design dual-target paradigms utilizing high-purity compounds from our extensive catalog of all peptides and small molecules.

The combination of CJC-1295 (No DAC) and 5-Amino-1MQ represents an intersection between endocrine receptor agonism and intracellular enzymatic modulation. While CJC-1295 (No DAC) is a 29-amino-acid tetrasubstituted peptide analog of growth hormone-releasing hormone (GHRH), 5-Amino-1MQ is a membrane-permeable small-molecule quinoline derivative. Investigating these distinct chemical entities side-by-side allows laboratory researchers to map downstream physiological responses across metabolic and anabolic pathways.

CJC-1295 (No DAC) Mechanism: GHRH Receptor Activation & Tissue Repair Models

CJC-1295 (No DAC), also known as Modified GRF (1-29), functions as a potent synthetic GHRH analog. Preclinical studies show that CJC-1295 (No DAC) acts as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. By binding selectively to the growth hormone-releasing hormone receptor (GHRH-R) on anterior pituitary somatotropes, the compound stimulates adenylate cyclase, elevating intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA) signaling.

Unlike native GHRH (1-29), which exhibits a rapid plasma half-life due to cleavage by dipeptidyl peptidase-IV (DPP-IV), CJC-1295 (No DAC) incorporates four strategic amino acid substitutions: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These modifications significantly improve enzymatic stability while maintaining physiological pulsatile GH release, avoiding the continuous elevation associated with DAC-containing variants. In rodent models, this controlled amplification of growth hormone secretion enhances downstream insulin-like growth factor 1 (IGF-1) expression, driving cellular proliferation, protein synthesis, and extracellular matrix remodeling.

5-Amino-1MQ Mechanism: NNMT Inhibition and Cellular Energy Dynamics

In contrast to receptor-mediated peptide signaling, 5-Amino-1MQ acts inside the cell as a selective, competitive inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT is a cytosolic enzyme predominantly expressed in adipose, liver, and muscle tissue that catalyzes the methylation of nicotinamide (NAM) into 1-methylnicotinamide (1-MNA), utilizing S-adenosylmethionine (SAM) as the primary methyl donor.

In vitro data indicate that elevated NNMT activity depletes intracellular NAM and SAM pools, directly suppressing the nicotinamide adenine dinucleotide (NAD+) salvage pathway and altering cellular epigenetics via histone hypomethylation. By selectively inhibiting NNMT, 5-Amino-1MQ restores cellular NAM availability, driving increased synthesis of NAD+ via nicotinamide phosphoribosyltransferase (NAMPT). This elevation in NAD+ levels enhances mitochondrial oxidative phosphorylation, boosts ATP yield, and activates silent information regulator 2 homolog 1 (SIRT1), a key regulator of metabolic homeostasis.

Theoretical Rationale for Concurrent Research Models

Researchers investigate CJC-1295 (No DAC) alongside 5-Amino-1MQ due to their distinct yet non-overlapping bioenergetic and anabolic pathways. Tissue regeneration requires both signaling triggers—such as elevated IGF-1 driven by GHRH receptor stimulation—and sufficient cellular energy, which depends on high NAD+/NADH ratios within the mitochondria.

In cell culture models of myogenesis or wound healing, GHRH analog activity promotes amino acid uptake and myofibrillar protein accretion. Simultaneously, NNMT inhibition optimizes mitochondrial ATP generation, preventing cellular exhaustion during protein synthesis. Preclinical models explore whether pairing these mechanisms yields additive or synergistic outcomes in cellular repair, adipocyte metabolism, and muscle tissue maintenance under metabolic stress.

Current State of Preclinical Evidence: What Data Shows and Lacks

It is critical for laboratory investigators to recognize the current boundaries of published science. While extensive literature exists for CJC-1295 (No DAC) in growth hormone research and for 5-Amino-1MQ in metabolic enzyme kinetics, direct combination studies combining both agents in a single experimental model are exceedingly limited in peer-reviewed literature.

Current hypotheses regarding their dual administration stem primarily from cross-referencing independent preclinical datasets. Animal studies involving CJC-1295 (No DAC) demonstrate clear GH pulse amplification, while separate rodent models evaluating 5-Amino-1MQ demonstrate reduced diet-induced adiposity and elevated intracellular NAD+. Because concurrent exposure data remains sparse, laboratory teams must establish controlled baseline assays to accurately quantify cross-pathway interactions, target engagement, and metabolic flux.

Assay-Design Considerations for Dual-Compound Protocols

When designing in vitro or animal research protocols to evaluate CJC-1295 (No DAC) and 5-Amino-1MQ, researchers must carefully control for kinetic and operational variables. In cell culture models, media composition, serum concentration, and incubation timing significantly influence observed outputs. Researchers looking into broader endocrinological pathways can explore our general research library hub for underlying biochemical frameworks.

Key design parameters include:

1. Direct vs. Staggered Treatment: Determining whether concurrent exposure or sequential administration yields clearer biomarker elevation (e.g., measuring p-AKT via CJC-1295 vs. NAD+/NADH ratio via 5-Amino-1MQ).

2. Metabolic Endpoint Selection: Utilizing quantitative assays such as LC-MS/MS for intracellular SAM/SAH and NAD+ quantification, paired with ELISA screening for IGF-1 and growth hormone secretion profiles.

3. Solvency Control: Accounting for solvent vehicles (e.g., vehicle controls for DMSO used in small-molecule delivery) to ensure observed toxicities or cellular shifts are strictly compound-driven.

Separate vs. Co-Reconstitution Handling and Solubility

A primary methodological error in dual-compound research involves physical co-reconstitution. CJC-1295 (No DAC) is a hydrophilic peptide supplied as a lyophilized powder, requiring reconstitution with sterile or bacteriostatic water to form a stable aqueous solution. Conversely, 5-Amino-1MQ is a hydrophobic small molecule that generally requires organic solvents such as dimethyl sulfoxide (DMSO) or specialized ethanol/surfactant systems for complete dissolution.

Attempting to combine lyophilized CJC-1295 (No DAC) and 5-Amino-1MQ powder into a single aqueous vial will lead to immediate precipitation, compound degradation, or altered peptide secondary structure. Each compound must be reconstituted independently in its appropriate solvent matrix. For precise dilution protocols and stock volume measurements, laboratory personnel should utilize the PX1 Research reconstitution calculator.

Storage, Thermal Stability, and Handling Guidelines

Maintaining structural integrity across both compounds requires strict adherence to temperature and environmental storage controls:

CJC-1295 (No DAC): Lyophilized powder should be stored desiccated at -20°C or -80°C for long-term stability. Avoid repeated freeze-thaw cycles. Once reconstituted with bacteriostatic water, aqueous stock solutions must be kept at 2–8°C and evaluated within short experimental windows to prevent hydrolytic degradation or deamidation.

5-Amino-1MQ: The raw powder is stable at room temperature in a desiccated, light-protected container, though long-term storage at -20°C is recommended. Stock solutions prepared in DMSO should be aliquoted and frozen at -80°C to prevent moisture absorption and autoxidation.

Comparative Analysis: Secretagogues and Metabolic Regulators in Research

To contextualize CJC-1295 (No DAC) within secretagogue science, researchers often compare it against other GHRH derivatives and ghrelin receptor agonists. For instance, tesamorelin incorporates a trans-3-hexenoic acid group that enhances resistance to DPP-IV enzymatic cleavage compared to standard GHRH analogs. Meanwhile, growth hormone secretagogues operating via the growth hormone secretagogue receptor (GHSR-1a)—such as ipamorelin and hexarelin—stimulate GH release through a distinct pathway that acts synergistically with GHRH signaling.

While secretagogues primarily drive anabolic cascades via pituitary stimulation, small molecules like 5-Amino-1MQ operate fundamentally downstream at the cell autonomous level. Comparing these classes highlights how receptor-targeted peptides modify systemic signaling while enzyme inhibitors alter localized cellular energetics.

Sourcing High-Purity Compounds: Analytical Standards and COA Verification

Experimental reproducibility hinges on compound purity and verified chemical identity. In analytical research, impurities, endotoxins, or residual trifluoroacetic acid (TFA) salts can disrupt cellular assays and yield false-positive or irreproducible results.

PX1 Research manufactures all compounds in ISO 17025-accredited, GMP-compliant USA facilities. Every batch undergoes rigorous High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) analysis to guarantee >98% purity, alongside limulus amebocyte lysate (LAL) testing to confirm low endotoxin levels. Researchers can instantly verify lot-specific analytical documentation via our transparent certificate of analysis portal. Institutional purchase orders and high-volume assay requirements can be managed through our dedicated wholesale lab accounts.